SCHEMBL4185896

SCHEMBL4185896

O=C(NC(c1ccccc1)C12CCC(CC1)CN2)c1cc(C(F)(F)F)ccc1C(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 13/20 0.57
PSMB11 A5LHX3 5/20 0.41
PSMA7 O14818 5/20 0.41
PSMB1 P20618 5/20 0.41
PSMA1 P25786 5/20 0.41
PSMA2 P25787 5/20 0.41
PSMA3 P25788 5/20 0.41
PSMA4 P25789 5/20 0.41
PSMB8 P28062 5/20 0.41
PSMB9 P28065 5/20 0.41
PSMA5 P28066 5/20 0.41
PSMB4 P28070 5/20 0.41
PSMB6 P28072 5/20 0.41
PSMB5 P28074 5/20 0.41
PSMB10 P40306 5/20 0.41
PSMB3 P49720 5/20 0.41
PSMB2 P49721 5/20 0.41
PSMA6 P60900 5/20 0.41
PSMA8 Q8TAA3 5/20 0.41
PSMB7 Q99436 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193318 0.90 SLC6A9 (0.56) SLC6A9
SCHEMBL4195768 0.83 SLC6A9 (0.66) SLC6A9
SCHEMBL4189152 0.83 SLC6A9 (0.66) SLC6A9
SCHEMBL4188979 0.83 SLC6A9 (0.66) SLC6A9
SCHEMBL4182595 0.83 SLC6A9 (0.66) SLC6A9
SCHEMBL13949282 0.83 SLC6A9 (0.66) SLC6A9
SCHEMBL4195738 0.80 SLC6A9 (0.62) SLC6A9
SCHEMBL4195500 0.80 SLC6A9 (0.62) SLC6A9
SCHEMBL13949251 0.80 SLC6A9 (0.73) SLC6A9
SCHEMBL13949276 0.80 SLC6A9 (0.73) SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US claimed
WO-2009013535-A1 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR ASTRAZENECA AB (SE) 2009-01-29 WO claimed
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
US-20090030033-A1 Novel Compounds 894 ASTRAZENECA AB (SE) 2009-01-29 US disclosed
WO-2009013535-A1 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR ASTRAZENECA AB (SE) 2009-01-29 WO disclosed
WO-2009013535-A1 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR ASTRAZENECA AB (SE) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030033-A1 Novel Compounds 894 AZI2, TPMT, AMPD2 SLC6A9 4382/4885PSMB11 4845/4885PSMA7 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.